Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and future antithrombotic agents in children.

Guy Young1

  • 1Children's Hospital of Orange County, 455 S. Main Street, Orange, CA 92868, USA. gyoung@choc.org

Expert Review of Cardiovascular Therapy
|July 1, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Blood advances·2026
Same author

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents.

American journal of hematology·2026
Same author

Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring.

Clinics in laboratory medicine·2026
Same author

New Treatment in Haemophilia: Challenges, Controversies and Uncertainties.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half-Life FVIII versus Non-FVIII Therapies.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

From nothing to abundance for hemophilia with inhibitors.

Blood·2026

Pediatric thromboembolic events are rising, prompting increased anticoagulation use. Novel agents like direct thrombin inhibitors offer potential advantages over traditional heparin and warfarin for children.

Area of Science:

  • Pediatric Hematology
  • Pharmacology
  • Thrombosis Management

Background:

  • Increasing incidence of thromboembolic complications in pediatric patients.
  • Expanded use of anticoagulation in children without robust clinical trial data.
  • Limitations of traditional anticoagulants (heparin, warfarin) in pediatric populations.

Purpose of the Study:

  • Review current and novel anticoagulation agents for pediatric use.
  • Highlight potential advantages of newer agents over established therapies.
  • Discuss the role of emerging anticoagulants in managing pediatric thrombosis.

Main Methods:

  • Literature review of anticoagulation therapies in children.
  • Analysis of pharmacologic properties of heparin, low-molecular-weight heparin, direct thrombin inhibitors, and Factor Xa inhibitors.

Related Experiment Videos

  • Examination of ongoing clinical trials for novel agents.

    • Main Results:

    • Heparin and warfarin are common but have limitations in children.
    • Low-molecular-weight heparin offers improved properties.
    • Novel agents like direct thrombin inhibitors (argatroban, bivalirudin) and fondaparinux show promise but require further study.

    Conclusions:

    • Novel anticoagulants present potential benefits for pediatric thrombosis.
    • Further research and clinical trials are essential to define optimal use and dosing in children.
    • Emerging agents may offer safer and more effective anticoagulation strategies for pediatric patients.